Lipoprotein disorders: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Lipoprotein disorders}}
{{Lipoprotein disorders}}
{{CMG}}; {{AE}} {{Rim}}, {{HP}}
{{CMG}}; {{AE}} {{Rim}}, {{HP}}, {{TarekNafee}}, {{PTD}}, {{AKI}}, {{UT}}, {{SCh}}, {{VD}}


==[[Lipoprotein disorders overview|Overview]]==
==Overview==
Lipoproteins, which are aggregates of proteins and lipids, allow the circulation of hydrophobic lipids in the body. Disorders of lipids and lipoproteins metabolism have important health consequences, mainly on the cardiovascular system. Lipoprotein disorders can be described as abnormalities in the level of the lipids, which include cholesterol and triglycerides, or as abnormalities in the levels of lipoproteins that include LDL, HDL, VLDL and chylomicrons.


==[[Lipoprotein disorders historical perspective|Historical Perspective]]==
Lipoprotein disorders have been initially classified in 1967 into different phenotypes by Fredrickson according to the type of lipoproteins that accumulate. However; Fredrickson's classification of hyperlipoproteinemias took into consideration the elevation in chylomicrons, LDL, VLDL but did not include abnormalities in HDL levels. Other classifications have been suggested, one of which is the National Cholesterol Education Program (NCEP) classification of lipoprotein disorders. NCEP classifies lipid disorders according to laboratory cut off points for the levels of total cholesterol, LDL-C and HDL.


==[[Lipoprotein disorders classification|Classification]]==
Lipoprotein disorders can be classified according to different criteria. First of all, lipoprotein disorders can be classified as primary disorders resulting from genetic mutations and secondary to other diseases. Another way of classifying lipoprotein disorders is as hypolipidemia (or hypolipoproteinemia) and hyperlipidemia (hyperlipoproteinemia) where the lipoprotein levels are decreased and increased respectively. However, the latter classification is not precise and creates some ambiguity, because some people can be labeled as having hyperlipidemia but have simultaneously high level of some lipoproteins and low levels of other lipoproteins depending on the underlying pathophysiology. Hence, a better term to describe the constellation of abnormal lipid profiles is "disorders of lipoproteins", or dyslipoproteinemia or dyslipidemia.
[[Hyperlipoproteinemia]] | [[Hypolipoproteinemia]]


==[[Lipoprotein disorders pathophysiology|Pathophysiology]]==
==Classification==


==[[Lipoprotein disorders causes|Causes]]==
==Genetics==
 
Shown below is a table summarizing the different genetic lipoprotein disorders along with the the gene and main lipoprotein involved in each disease.  For detailed information about each disease, click on its name.
==[[Lipoprotein disorders differential diagnosis|Differentiating Lipoprotein disorders from other Disorders]]==
 
==[[Lipoprotein disorders epidemiology and demographics|Epidemiology and Demographics]]==
 
==[[Lipoprotein disorders risk factors|Risk Factors]]==
 
==[[Lipoprotein disorders screening|Screening]]==
 
==[[Lipoprotein disorders natural history, complications, and prognosis|Natural History, Complications, and Prognosis]]==
 
==Diagnosis==
[[Lipoprotein disorders history and symptoms|History and Symptoms]] | [[Lipoprotein disorders physical examination|Physical Examination]] | [[Lipoprotein disorders laboratory findings|Laboratory Findings]] | [[Lipoprotein disorders electrocardiogram|Electrocardiogram]] | [[Lipoprotein disorders x ray|X Ray]] | [[Lipoprotein disorders CT|CT]] | [[Lipoprotein disorders MRI|MRI]] | [[Lipoprotein disorders echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Lipoprotein disorders other imaging findings|Other Imaging Findings]] | [[Lipoprotein disorders other diagnostic studies|Other Diagnostic Studies]]
 
==Treatment==
[[Lipoprotein disorders medical therapy|Medical Therapy]] | [[Lipoprotein disorders surgery|Surgery]] | [[Lipoprotein disorders primary prevention|Primary Prevention]] | [[Lipoprotein disorders secondary prevention|Secondary Prevention]] | [[Lipoprotein disorders cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Lipoprotein disorders future or investigational therapies|Future or Investigational Therapies]]
 
==Case Studies==
[[Multiple endocrine neoplasia type 4 case study one|Case #1]]
 
==[[Lipoprotein disorders landmark trials|Landmark Trials]]==


{| class="wikitable sortable" style="font-size:90%"
! '''Genetic Lipoprotein Disorder'''
! '''Gene Involved'''
! '''Main Lipoprotein Involved'''
|-
| [[Familial hypercholesterolemia]] || LDL-R || LDL
|-
| Familial defective apo B100|| Apo B || LDL
|-
| Autosomal dominant hypercholesterolemia || PCSK9 || LDL
|-
| Autosomal recessive hypercholesterolemia || ARH || LDL
|-
| [[Abetalipoproteinemia]] || MTP || LDL
|-
| [[Hypobetalipoproteinemia]] || Apo B || LDL
|-
| Familial sitosterolemia || ABCG5 - ABCG8|| LDL
|-
| Familial lipoprotein(a) hyperlipoproteinemia || Apo(a)|| LDL
|-
| Dysbetalipoproteinemia type III || Apo E ||
|-
| Hepatic lipase deficiency|| HL ||
|-
| [[Lipoprotein lipase deficiency]] || LPL|| Chylomicron
|-
| Apo C-II deficiency|| Apo C-II || Chylomicron
|-
| Apo A-V deficiency || Apo A-V deficiency || Chylomicron
|-
| [[Familial hypertriglyceridemia]] || Multiple genes||
|-
| [[Familial combined hyperlipidemia]]|| Multiple genes||
|-
| [[Familial hypoalphalipoproteinemia]]|| ||
|-
| GPIHBP1 deficiency|| GPIHBP1|| Chylomicron
|-
| [[Apo A-I]] deficiency|| Apo A-I || HDL
|-
| [[Tangier disease]] || ABCA1|| HDL
|-
| Familial [[LCAT deficiency]]|| LCAT || HDL
|-
| [[CETP]] deficiency || CETP|| HDL
|-
| Type A [[Niemann-Pick disease]]|| SMPD1|| HDL
|-
| Type B Niemann-Pick disease|| SMPD1|| HDL
|-
| Type C Niemann-Pick disease|| NPC1|| HDL
|-
| [[PCSK9]] deficiency|| PCSK9|| HDL
|-
| [[Chylomicron retention disease]]
|SAR1B
|Multiple
|}
==References==
==References==
{{reflist|2}}
{{reflist|2}}
Line 41: Line 80:


[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Endocrinology]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 18:07, 8 November 2016

Lipoprotein Disorders Microchapters

Patient Information

Overview

Causes

Classification

Hyperlipoproteinemia
Hypolipoproteinemia

Treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2], Hardik Patel, M.D., Tarek Nafee, M.D. [3], Prince Tano Djan, BSc, MBChB [4], Aravind Kuchkuntla, M.B.B.S[5], Template:UT, Shivani Chaparala M.B.B.S [6], Vishal Devarkonda, M.B.B.S[7]

Overview

Lipoproteins, which are aggregates of proteins and lipids, allow the circulation of hydrophobic lipids in the body. Disorders of lipids and lipoproteins metabolism have important health consequences, mainly on the cardiovascular system. Lipoprotein disorders can be described as abnormalities in the level of the lipids, which include cholesterol and triglycerides, or as abnormalities in the levels of lipoproteins that include LDL, HDL, VLDL and chylomicrons.

Lipoprotein disorders have been initially classified in 1967 into different phenotypes by Fredrickson according to the type of lipoproteins that accumulate. However; Fredrickson's classification of hyperlipoproteinemias took into consideration the elevation in chylomicrons, LDL, VLDL but did not include abnormalities in HDL levels. Other classifications have been suggested, one of which is the National Cholesterol Education Program (NCEP) classification of lipoprotein disorders. NCEP classifies lipid disorders according to laboratory cut off points for the levels of total cholesterol, LDL-C and HDL.

Lipoprotein disorders can be classified according to different criteria. First of all, lipoprotein disorders can be classified as primary disorders resulting from genetic mutations and secondary to other diseases. Another way of classifying lipoprotein disorders is as hypolipidemia (or hypolipoproteinemia) and hyperlipidemia (hyperlipoproteinemia) where the lipoprotein levels are decreased and increased respectively. However, the latter classification is not precise and creates some ambiguity, because some people can be labeled as having hyperlipidemia but have simultaneously high level of some lipoproteins and low levels of other lipoproteins depending on the underlying pathophysiology. Hence, a better term to describe the constellation of abnormal lipid profiles is "disorders of lipoproteins", or dyslipoproteinemia or dyslipidemia.

Classification

Genetics

Shown below is a table summarizing the different genetic lipoprotein disorders along with the the gene and main lipoprotein involved in each disease. For detailed information about each disease, click on its name.

Genetic Lipoprotein Disorder Gene Involved Main Lipoprotein Involved
Familial hypercholesterolemia LDL-R LDL
Familial defective apo B100 Apo B LDL
Autosomal dominant hypercholesterolemia PCSK9 LDL
Autosomal recessive hypercholesterolemia ARH LDL
Abetalipoproteinemia MTP LDL
Hypobetalipoproteinemia Apo B LDL
Familial sitosterolemia ABCG5 - ABCG8 LDL
Familial lipoprotein(a) hyperlipoproteinemia Apo(a) LDL
Dysbetalipoproteinemia type III Apo E
Hepatic lipase deficiency HL
Lipoprotein lipase deficiency LPL Chylomicron
Apo C-II deficiency Apo C-II Chylomicron
Apo A-V deficiency Apo A-V deficiency Chylomicron
Familial hypertriglyceridemia Multiple genes
Familial combined hyperlipidemia Multiple genes
Familial hypoalphalipoproteinemia
GPIHBP1 deficiency GPIHBP1 Chylomicron
Apo A-I deficiency Apo A-I HDL
Tangier disease ABCA1 HDL
Familial LCAT deficiency LCAT HDL
CETP deficiency CETP HDL
Type A Niemann-Pick disease SMPD1 HDL
Type B Niemann-Pick disease SMPD1 HDL
Type C Niemann-Pick disease NPC1 HDL
PCSK9 deficiency PCSK9 HDL
Chylomicron retention disease SAR1B Multiple

References

Template:WH Template:WS